Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics

Elevated low-density lipoprotein cholesterol (LDL-C) is one of the major contributors to cardiovascular heart disease (CHD), the leading cause of death worldwide. Due to severe side effects of statins, alternative treatment strategies are required for statin-intolerant patients. Monoclonal antibodie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular therapy 2019-01, Vol.27 (1), p.188-199
Hauptverfasser:	Khoshnejad, Makan, Patel, Ami, Wojtak, Krzysztof, Kudchodkar, Sagar B., Humeau, Laurent, Lyssenko, Nicholas N., Rader, Daniel J., Muthumani, Kar, Weiner, David B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - therapeutic use Cardiovascular disease Cardiovascular Diseases - blood Cardiovascular Diseases - drug therapy Cardiovascular Diseases - therapy Cholesterol Cholesterol, LDL - blood Clinical trials Coronary artery disease Deoxyribonucleic acid DNA gene therapy Genetic Therapy - methods Heart diseases HEK293 Cells High density lipoprotein Humans Immunoglobulins Kexin Lipids Low density lipoprotein Mice Monoclonal antibodies Mutation Original Patients PCSK9 inhibitor Pharmaceuticals Plasmids Plasmids - genetics Proprotein Convertase 9 - immunology Proprotein convertases Proteins Statins Stock options Subtilisin Viral infections
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!